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doi:10.1016/j.jmii.2010.08.005Background: Hepatosplenic fungal infection (HSF) is a distinct form of invasive fungal infection
with main involvement of the liver, spleen, and occasionally the kidney. In this study, we inves-
tigated the clinical characteristics and outcomes of patients with HSF in childhood.
Methods: We retrospectively reviewed pediatric patients with the diagnosis of HSF in a tertiary
medical center in Taiwan between July 1999 and June 2009. The definition of HSF included
imaging studies demonstrating multiple focal lesions in the liver and/or spleen with or without
a microbiologic evidence for fungal infection. The clinical characteristics and outcomes were
analyzed.
Results: We identified 15 pediatric patients with HSF. Eleven patients had diagnosis of hemato-
oncologic malignancy, and two patients had severe aplastic anemia. All patients had fever, and
most patients had abdominal pain, nausea, vomiting, and hepatosplenomegaly. The detection
rate of computed tomography scan (15/15, 100%) was superior to abdominal sonography (10/
15, 67%, pZ 0.01). Ten (91%) of the 11 patients with microbiologic evidence were infected by
Candida species. Neither recurrence nor breakthrough fungal infection was noted when the
patients underwent further chemotherapy and stem cell transplantation. Six patients (40%)
died before the end of the study, but no mortality was directly related to HSF.
Conclusion: Candida species was the major pathogen for HSF, and computed tomography scan
was a good diagnostic tool to detect the multiple focal lesions. Under adequate antifungal
treatment, HSF could be cured without recurrence in spite of further chemotherapy and stem
cell transplantation.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.of Pediatric, National Taiwan University Hospital, College of Medicine, National Taiwan University,
0016, Taiwan.
ed.net.tw, lychang@ntu.edu.tw (L.-Y. Chang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Hepatosplenic fungal infection in childhood 297Introduction
Hepatosplenic fungal infection (HSF) is recognized as
a distinct form of chronic disseminated fungal infection
with main involvement of the liver, spleen, and occasion-
ally the kidneys. This condition was first reported by Bodey
et al.1 in 1969, and the incidence of HSF has significantly
increased since 1980,2 but it is still uncommon. It occurred
almost exclusively in individuals with impaired host defense
mechanisms, especially in patients with hemato-oncologic
malignancy undergoing antineoplastic chemotherapy, and
may occur in patients with chronic granulomatous diseases,
Crohn’s disease, diabetes mellitus, and patients receiving
corticosteroid therapy.3 The incidence of HSF ranged from
3% to 29.1% in patients with hematologic malignancy
undergoing chemotherapy or hematopoietic stem cell
transplantation.2,4e7 Some cases had been reported in
children since 1980s,8e10 but the incidence of HSF in pedi-
atric patient remained unclear.
Although laboratory tests usually showed increased level
of serum C-reactive protein, elevated hepatic transaminase
[aspartate transferase, alanine transferase], and alkaline
phosphatase,11 they were not diagnostic of HSF. As for
imaging studies, computed tomography (CT) and magnetic
resonance imaging (MRI) are superior to ultrasonography to
detect hepatosplenic lesions.11e13 Because blood culture
was yielded in less than 50% of cases, deep-tissue specimen
may not always demonstrate fungal infection11,14,15 and the
imaging studies usually revealed the lesions until the
recovery of neutrophil counts,16 early diagnosis of HSF was
extremely difficult. In addition, the optimal treatment of
HSF and the duration of treatment were still disputable.6
To clarify the uncertain conditions mentioned above, we
retrospectively reviewed the pediatric patients with HSF in
Taiwan to aim at the incidence for pediatric leukemia
patients, clinical characteristics, and treatment outcome.
Methods
Patients
We retrospectively reviewed the pediatric patients who
were admitted to National Taiwan University Hospital,
a tertiary medical center from July 1999 to June 2009, in
Taipei, Taiwan. We searched discharge diagnosis with
implantable cardioverter-defibrillator code: 572.0 for liver
abscess, 682.9 for abscess, and 117.0e117.8 for invasive
fungal disease to identify the patients with HSF. The diag-
nosis of HSF was based on blood cultures, clinical studies,
histological studies, and imaging studies. The demographic
features, disease status before and after diagnosis of HSF,
microbiological and radiological evidence of HSF, choice of
antifungal therapy, and outcome were analyzed.
Definition for HSF
The definition of HSF was modified according to the criteria
for invasive fungal infection established by the European
Organization for Research and Treatment of Cancer/Mycoses
Study Group in 2002 and the revised definitions in
2008.17,18 The original criteria of HSF were limited toimmunocompromised patients, and we modified the criteria
to fit all pediatric groups as the following: theprovenHSFwas
defined when there was radiologic evidence of fungal
infection with multiple focal lesions in the liver and/or
spleen and a specific diagnosis of fungal infection was
established by the presence of fungi in deep-tissue biopsy, or
aspiration specimens by culture, histological examination, or
polymerase chain reaction (PCR) result, or blood culture;
probable HSF was defined with typical imaging evidence and
positive serum fungal antigen test (serum galactomannan
test for Aspergillus spp); possible HSF was defined only with
typical imaging study evidence. Patients who had invasive
fungal infection (such as candidemia) without evidence of
liver or spleen involvement were excluded from this study.
Laboratory data and imaging studies
Complete blood counts and a panel of blood chemistry,
including hepatic transaminase, lactate dehydrogenase,
alkaline phosphatase, blood urea nitrogen, creatinine, and
electrolytes, were examined at least weekly during the
hospital stay. At least one set of blood culture was done at
the onset of fever and was frequently repeated if fever
persisted. Liver tissue was obtained by blind needle aspi-
ration or laparotomy biopsy on some patients. All biopsy
specimens were submitted for cultures, pathological
examinations, and some specimens were sent for fungal
PCR assay if indicated. Serum galactomannan test was
performed as indicated. Imaging studies including chest X-
ray, CT scan, ultrasonography, MRI, and gallium scan were
performed as needed in each patient.
Antineoplastic therapy
Patients in this study received antineoplastic therapy for
acute lymphoblastic leukemia, acute myeloid leukemia,
neuroblastoma, and hematopoietic stem cell trans-
plantation for their underlying diseases. Antineoplastic
chemotherapy was continued during the course of anti-
fungal therapy to treat the primary neoplastic process on
schedule, as aggressively as possible. Nine patients had
attenuated modification of their antineoplastic therapy,
consisting of a delay of a cycle in eight patients and
modification of dosage in one patient.
Antifungal therapy
The initial antifungal regimen consisted of amphotericin B,
1.0 mg/kg/d or fluconazole 400 mg/d. Follow-up or salvage
regimens included amphotericin B (1 mg/kg/d), fluconazole
(6e12 mg/kg/d or 400e800 mg/d), liposomal amphotericin
B (5 mg/kg/d), caspofungin (70 mg/m2/d initially, then
50 mg/m2/d), or voriconazole (4e8 mg/kg/d).
Response
Response to antifungal treatment was assessed mainly by
serial imaging studies, clinical evaluation, and laboratory
examination. Complete response was defined as resolution
of all symptoms and signs attributable to HSF, negative
blood culture for fungus, and disappearance of fungal
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greater than 50% reduction of the number of lesions by
imaging study. Stabilized HSF was defined as no further
development of new lesions, no expansion of existing lesion
size, and no clinical deterioration. Recurrent HSF was
defined as development of new lesions after complete
radiological resolution or calcification of lesions. Break-
through fungemia was defined as blood culture proven
invasive fungal infection.
Statistics
Comparisons of selected parameters were performed by c2
test. A p value<0.05 was considered statistically significant.
Results
Demography and diagnosis
From July 1999 to June 2009, HSF was diagnosed in 15 of the
pediatric patients in National Taiwan University Hospital,
and the characteristics were summarized in Table 1. During
this period, we newly diagnosed 92 patients with acute
myeloid leukemia and 252 patients with acute lymphoblastic
leukemia undergoing antineoplastic chemotherapy in thisTable 1 Characteristics of 15 patients with hepatosplenic
fungal infection
Characteristics




Clinical status (n Z 15)
Underlying disease:
Acute lymphoblastic leukemia 5 (33)
Acute myeloid leukemia 5 (33)
Very severe aplastic anemia 2 (13)
Neuroblastoma 1 (7)
Biliary atresia with hepatic failure 1 (7)
Newborn 1 (7)
Prior neutropeniaa 12 (80)
Prior bacteremiab 3 (20)
Recent broad-spectrum antibioticsc 13 (87)
Status of hemato-oncologic
disease (n Z 13)
Newly diagnosed 7 (54)
Remission 3 (23)




a Neutropenia (absolute neutrophil count < 500/mm2) within
2 wk before the onset of hepatosplenic fungal infection.
b Bacteremia diagnosed within 2 wk before the onset of
hepatosplenic fungal infection.
c Broad-spectrum antibiotics (third cephalosporin at least)
used within 2 wk before the onset of hepatosplenic fungal
infection.period. The incidence of HSF was not significantly different
between the patients with acute myeloid leukemia (AML, 5/
92, 5.4%) and those with acute lymphoblastic leukemia (ALL,
5/252, 2.0%, pZ 0.09). Two patients were diagnosed of very
severe aplastic anemia; onewas diagnosed simultaneously of
HSF and aplastic anemia on his first time visit, and the other
was just received peripheral blood stem cell transplant.
Twelve (80%) patients ever had prior neutropenic episodes
(absolute neutrophil count less than 500/mm2) before the
onset of HSF, and only four patients (27%) remained neu-
tropenic on the time when an image study confirmed the
diagnosis of HSF. Beside, the majority (87%) of patients had
exposure to broad-spectrum antibiotics 2 weeks before the
onset of HSF, and only three patients (20%) had the confirmed
diagnosis of bacteremia (Escherichia coli in two and methi-
cillin-sensitive Staphylococcus aureus in one). The blood
cultures yielded positive bacterial results initially and then
became sterile after antibiotic treatment. The therapeutic
antibiotics for two patients with E coli bacteremia were
piperacillin/tazobactam plus gentamicin initially, and then
shifted to cefepime plus amikacin, and then vancomycin plus
meropenem because of persistent fever. The patient with
methicillin-sensitive Staphylococcus aureus bacteremia
received oxacillin therapy for 14 days.
Table 2 shows the clinical presentation and laboratory
data. All patients had fever, and more than 70% of patients
had abdominal pain, nausea, vomiting, and hep-
atosplenomegaly (Table 2). Six patients (40%) presented
cutaneous lesions, which were important clinical signs for
invasive fungal infection. The peak C-reactive protein
concentration was moderately elevated [>5 mg/dL
(normal, <0.8 mg/dL)] in 13 (87%) of the 15 patients. The
peak serum levels of aspartate transferase, alanine trans-
ferase, alkaline phosphatase, g-glutamyl transpeptidase,
and total bilirubin were normal in 17%, 13%, 33%, 40%, and
27% of the patients, respectively.
Multifocal lesions were demonstrated in all patients by
imaging studies. Both abdominal CT scan and ultrasonog-
raphy were performed in all patients. CT scan had a signif-
icantly higher detection rate (15/15, 100%) than abdominal
ultrasonography (10/15, 67%, p Z 0.01). Only three
patients received MRI study, and two of them revealed
positive findings. The liver was the most commonly involved
organ (15/15, 100%), followed by the spleen (10/15, 67%),
the kidney (8/15, 53%) (Fig. 1), the lung, and the venous
thrombosis (2/15, 13%) (Fig. 2).
Pathogens of HSF
Ten patients had proven HSF, one probable infection, and
four possible infection (Table 3). All patients received blood
cultures for fungus, and six patients (40%) had positive
culture results, including Candida tropicalis in three,
Candida albicans in two, and Candida krusei in one. A total
of eight patients received liver biopsies after administra-
tion of antifungal therapy, and five patients had evidence
of fungal infection by histopathologic examination of the
liver biopsy specimens (four patients) or Candida PCR (one
patient). Overall, among the 11 patients with definite
pathogens, Candida species were the causative pathogen in
10 (91%) of them. Though the fungal infection was not
confirmed by blood culture or examination of the tissue
Table 2 Clinical characteristics and laboratory data in patients with hepatosplenic fungal infection
Clinical characteristics No. of patients (%) Laboratory data Mean (range)
Fever > 38C 15 (100) Peak CRP (mg/dL) 18.7 (3.6e29.9)
Abdominal pain 12 (80) Peak AST (U/L) 315.5 (20.0e2515.0)
Nausea and/or vomiting hepatosplenomegaly 12 (80) Peak ALT (U/L) 275.7 (24.0e775.0)
Jaundice 11 (73) Peak ALP (U/L) 815.7 (220.0e1989.0)
Cutaneous candidiasis 7 (47) Peak GGT (U/L) 215.6 (12.0e823.0)
Respiratory tract symptoms 6 (40) Peak total bilirubin (mg/dL) 9.6 (0.6e50.0)
8 (53)
ALPZ alkaline phosphatase; ALTZ alanine transaminase; ASTZ aspartate transaminase; CRPZ C-reactive protein; GGTZ g-glutamyl
transpeptidase.
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have possible HSF because of multifocal lesions in the liver
and/or spleen without evidence of infection caused by
other microorganisms.
Antifungal therapy and outcome
Table 3 shows the antifungal therapy, duration, and treat-
ment outcome. One patient received fluconazole therapy
empirically, but it was replaced by amphotericin B later
because of unresponsiveness to the drug and persistent
fever. Fourteen patients were treated with amphotericin B
in the beginning. Five of these patients later received
liposomal amphotericin B and two patients received cas-
pofungin because of nephrotoxicity (impaired renal func-
tion greater than 50%). One patient was given caspofungin
because of persistent fever and nephrotoxicity. Six patients
(40%) died during a median follow-up of 5 months (range:
2e8 months) because of progression of underlying diseases.
Ten patients received further chemotherapy after the
diagnosis of HSF. Although repeated neutropenic status
occurred after chemotherapy, there was no progression of
fungal infection or recurrence of previous fungal infection.
Among them, three patients underwent peripheral blood
hematopoietic stem cell transplantation later (range from
26 to 255 days after diagnosis of HSF). Two of them wereFigure 1. Computed tomography scan after recovery from
nadir post-chemotherapy reveals radiological multiple hypo-
densities within the liver, spleen, and bilateral kidneys (arrows).under amphotericin B prophylaxis, and another one was
under fluconazole prophylaxis. All of them survived the first
100 days posttransplantation. One patient had positive
findings on imaging before transplantation, but there was
no evidence of recurrence of prior fungal infection in all
patients. Because of progression of underlying diseases,
two patients died on Day þ123 and Day þ158 post-
transplantation, respectively.
Discussion
HSF is an uncommon but invasive infection, which has been
attributed to prolonged neutropenia, presence of intra-
vascular catheters, disruption of mucosal barriers, and
administration of broad-spectrum antibiotics. Our patients
mainly had hemato-oncologic malignancy undergoing
chemotherapy or hematopoietic stem cell transplantation.
Only two patients didn’t have chemotherapy before, both
of them have presence of intravascular catheters and
disruption of mucosal barriers.
The incidence of HSF ranged from 3% to 29.1% in patients
with hematologic malignancy undergoing chemotherapy or
hematopoietic stem cell transplantation, depending on the
diagnostic criteria used in adult patients.2,4e7,15,19 Although
there were several literatures discussing HSF in the pediatric
group before, the incidence of HSF in pediatric patient was
mentioned in three retrospective studies before. Verdeguer
et al.8 demonstrated the presence of hepatosplenicFigure 2. Computed tomography scan after recovery from
nadir of neutropenia post-chemotherapy reveals a radiological
single hypodense lesion within the inferior vena cava (arrow).
Table 3 Microbiologic evidence, treatment, and outcome of 15 patients with HSF









1 15/M Candida tropicalisa B/C AMB (3) L AMB/FCZ (11d) Partial þ/ Alive
2 13/F C tropicalisa B/C AMB (6) Caspo/FCZ (9d) Partial þ/ Alive
3 11/F C tropicalisa B/C AMB (8) Caspo/FCZ (2) Complete þ/ Alive
4 12/F Candida kruseia B/C AMB (21) L AMB/VRC (10d) Partial / Alive
5 0.1/F Candida albicansa B/C AMB (69) FCZ (4) Complete / Alive
6 2/F C albicansa B/C AMB (21) L AMB/FCZ (5.5) Stabilized þ/ Died
7 6/F Candida speciesa Liver biopsy AMB (45) FCZ (6) Stabilized þ/þ Died
8 1/M Candida speciesa Liver biopsy AMB (7) Caspo/VRC (33d) Complete þ/ Alive
9 2/M Candida speciesa Liver biopsy AMB (87) FCZ (10) Complete þ/þ Alive
10 8/F Candida speciesa Liver biopsy AMB (12) VRC (25) Complete / Alive
11 6/F Aspergillus sppb GM test AMB (51) L AMB/VRC (2) Persisted þ/ Died
12 14/F Unknownc d AMB (90) L AMB/VRC (13) Complete þ/ Alive
13 16/M Unknownc d AMB (60) FCZ (2.5) Stabilized / Died
14 17/M Unknownc d FCZ (8) AMB/FCZ (8) Complete þ/þ Died




d Still under antifungal therapy till the end of study.
AFT Z antifungal treatment; AMB Z conventional amphotericin B; Caspo Z caspofungin; B/C Z blood culture; CT Z chemotherapy;
F Z female; FCZ Z fluconazole; GM test Z serum galactomannan test; HCT Z hematopoietic stem cell transplantation;
HSF Z hepatosplenic fungal infection; L AMB Z liposomal amphotericin B; M Z male; VRC Z voriconazole.
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leukemia. In the study conducted by Lai et al.,10 the incidence
of HSF in pediatric patient with persistent febrile neutropenia
was 2.4%. Finally, HSFs were found in 2 (1.3%) of the 154 chil-
dren with acute leukemia receiving long-term antifungal
prophylaxis.20 Our study reveals that the incidence of HSF is
2.0% in pediatric patients with acute lymphoblastic leukemia
and 5.4% in patients with acute myeloid leukemia. However,
only prospective multicenter trials with uniform definition of
the termHSFwill be able to provide accuratedata that answer
this question.
HSF should be highly suspected in patients with pro-
longed and profound febrile neutropenia, especially if fever
recurs after recovery of neutropenia. In our study, seven
(58%) patients experienced persistent fever and five (42%)
had recurrent fever after recovery from neutropenia. In
addition, 80% of the patients complained of abdominal
pain, nausea, vomiting, and more than 70% of the patients
had hepatosplenomegaly. In adult patients, elevated serum
alkaline phosphatase levels can give a hint of an infiltrative
disorder of the liver and image studies should be per-
formed. However, the serum alkaline phosphatase level
was interfered by several factors, such as bone growth and
the normal range varied with different age group. Other-
wise, its response delayed after clinical improvement.
Therefore, it is difficult to make an early diagnosis of HSF
only depending on the clinical manifestations.
Serum galactomannan test has been well studied in the
detection of invasive aspergillosis in adult immunocompro-
mised patients. The sensitivity was 78% (61%e89%) and the
specificity was 81% (72%e88%) for an Optical Density Index
(ODI) of 0.5. When the ODI cut-off value increased to 1.5, the
sensitivity was 64% (50%e77%) and specificity was 95% (91%e
97%).21 Beside, Hayden et al.22 demonstrated the presence ofcirculating galactomannan is a predictive of invasive asper-
gillosis inmost pediatric oncology patients. Oneof our patients
was diagnosed with probable HSF only by the serum ODI value
1.7 initially, and this value was highly specific to invasive
Aspergillus infection. Therefore, the serum galactomannan
test could precede clinical, microbiologic, or radiographic
evidence of invasive aspergillosis.
Ultrasonography, CT scan, and MRI are clinically effective
for evaluation and follow-up of HSF;12,13,23 however, all
imaging techniques have tobe repeated in cases of suspected
fungal infection. Although MRI achieved higher diagnostic
accuracy of HSF than CT and ultrasonography in previous
studies,12,13,24 CT scan and ultrasonography are more widely
used and more cost-effective in Taiwan. Karthaus et al.25,26
reported serial ultrasonography up to twice a week had the
same detection rate and reliability of hepatosplenic abscess
compared with CT scan and MRI. However, we performed
both CT scan and abdominal ultrasonography nearly at the
same time in all of our patients to detect hepatosplenic
abscess after the recovery of neutropenia, and the result
revealed that CT scan had a better detection rate than
ultrasonography (100% vs. 67%, p Z 0.01). It is possibly
because of the limitation of study frequency, tools, and
expertise of operators in the latter examination. Beside,
hepatic or splenic lesions may transiently disappear during
neutropenia.16 In the same way, Anttila et al.11 analyzed the
findings of ultrasonography and CT scan of 14 patients that
were both performed within a 7-day period between Days 5
and 20 after each patient’s recovery from neutropenia, and
the detection rate for ultrasonography and CTscan were 43%
and 93% respectively. Thus we suggested CT scan should be
performed in pediatric patients who have suspected HSF
after the recovery of neutropenia although the ultrasonog-
raphy failed to reveal lesions.
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50%,deep-tissue specimenmaynotalwaysdemonstrate fungal
infection, and obtained tissue specimen is associated with
relative high risk of complications.11,14,15 The confirmation of
microbiology pathogen was difficult. In our study, we
confirmed11 patientswith definite pathogen,Candida species
were the most common causative pathogen (90.9%).
The optimal management of HSF and the antifungal
therapy for choice are not well established. Because HSF was
mainly caused by Candida species, fluconazole for stable or
nonneutropenic patients, and liposomal amphotericin B or
caspofungin for severely ill patients as the initial treatment
were suggested by the Infectious Disease Society of
America.27e29 In our experience, aggressive antifungal
therapy using conventional amphotericin B should initially be
given for neutropenic or unstable patients and the cost was
less expensive. If nephrotoxicity occurs, liposomal ampho-
tericinBorcaspofungin canbea goodalternativedrug forHSF.
After the disease status gets stabilized, oral form fluconazole
or voriconazole could be used as maintainable agent
depending on the drug susceptible pattern of the pathogen.
Hepatic or splenic lesions may transiently disappear during
neutropenia,16 thus antifungal therapy should not be dis-
continued on the basis of radiological findings alone.
Prior invasive fungal infection is a difficult problem for
subsequent chemotherapies and hematopoietic stem cell
transplantation. However, delaying the treatment schedule
because of persistent radiological lesions may potentially
have a negative impact on the underlying malignancy,
resulting in disease progression or relapse30 In this study, 10
patients received further chemotherapy with repeated
neutropenic episodes after the diagnosis of HSF, and there
was no progression of fungal infection or recurrence.
Among them, three patients underwent peripheral blood
hematopoietic stem cell transplantation later (26e255 days
after diagnosis of the HSF) under amphotericin B or fluco-
nazole prophylaxis. All of them survived the first 100 days
posttransplantation without recurrence infection. Our data
provide the evidence that HSF is not an absolute contrain-
dication for subsequent chemotherapy and hematopoietic
stem cell transplantation, if the infection can be controlled
with antifungal therapy before transplant and continued
until engraftment is established.4,6,15,16,30e33
In conclusion, HSF should be considered when hemato-
oncologic patients receiving chemotherapy have prolonged
neutropenic fever even after administration of broad-
spectrum antibiotics, especially if fever persists or recurs
after recovery of neutropenia. If abdominal pain, hep-
atosplenomegaly, nausea, and vomiting develop, CT rather
than ultrasonography of the abdomen should be performed
after recovery of the neutropenia. Under effective anti-
fungal therapy and closely imaging monitor, the mortality
directly caused by HSF was low in pediatric patients.
Therefore, chemotherapy and hematopoietic stem cell
transplantation for the underlying disease may be given to
patients if the infection has been adequately controlled.
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